Testing a new drug for non-Hodgkin lymphoma that has not improved with prior treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug that blocks a protein helping lymphoma grow and hide from your immune system. It's for people with certain types of non-Hodgkin lymphoma that haven't improved after at least two standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have a type of non-Hodgkin lymphoma (like DLBCL, MCL, MZL, PTCL, or CTCL) that has come back or hasn't responded to at least two prior treatments.
- You should be physically able to take care of yourself (ECOG score 0 or 1).
- You cannot have had certain immune therapy drugs (PD-1/PD-L1 inhibitors) within the last year.
- You should not have an active autoimmune disease that requires treatment, or serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests two new investigational drugs (SCTB35 and SCTB41) alone or with chemotherapy for people with B-cell lymphoma that hasn't responded to previous treatments. The goal is to see if these drugs can help shrink or control the lymphoma.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.